Imeik Technology Development (SHE:300896) plans to acquire 85% of South Korean peer Regen Biotech for up to $190 million, according to a Monday press release published on Futubull.
The stake will be bought through the Chinese biomedical soft tissue repair products manufacturer's joint venture, Imeik International.
The venture was established through Imeik's subsidiary, Imeik Hong Kong, and Shou Rui Hong Kong.
Imeik's shares surged less than 15% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments